Plasma phospho‐tau181 increases with Alzheimer's disease clinical severity and is associated with tau‐ and amyloid‐positron emission tomography

Abstract

We examined and compared plasma phospho‐tau181 (pTau181) and total tau: (1) across the Alzheimer's disease (AD) clinical spectrum; (2) in relation to brain amyloid β (Aβ) positron emission tomography (PET), tau PET, and cortical thickness; and (3) as a screening tool for elevated brain Aβ.

Document Details

Document Type
Pub Defense Publication
Publication Date
Apr 04, 2018
Source ID
10.1016/j.jalz.2018.02.013

Entities

People

  • Clifford Jack
  • Clinton E. Hagen
  • David C. Airey
  • David S. Knopman
  • Jeffrey L. Dage
  • Jing Xu
  • Mary M. Machulda
  • Michelle M. Mielke
  • Prashanthi Vemuri
  • Ronald C. Petersen
  • Rosebud O. Roberts
  • Val J. Lowe
  • Xiyun Chai

Organizations

  • Avid Radiopharmaceuticals
  • Eli Lilly and Company
  • GE HealthCare
  • Mayo Clinic
  • National Institutes of Health
  • United States Department of Defense

Tags

Fields of Study

  • Physics

Readers

  • Acoustical Oceanography.
  • Quantum spin resonance or Electron Paramagnetic Resonance spectroscopy.
  • Traumatic Brain Injury (TBI) and Cognitive Aging in the Guam and Border Populations Affected by Alzheimer's Disease and Tau-Associated Dementias.